After the Founder: How Adversity Shaped Lupin’s Next Generation
Nilesh’s responsibilities aligned well with his data-driven focus, attention to detail and ability to build loyal teams, characterized by an amiable, self-deprecating sense of humour and clear delegation of responsibility. His success in running Lupin’s research and technical operations, as well as the India business, made him a strategic leader.
Hyderabad: For Lupin, the years after Dr Desh Bandhu Gupta’s death were the first test of the ability of Lupin’s joint leadership structure to deal with tough times after a dream run since the millennium. It was a difficult time for the siblings Vinita Gupta and Nilesh Gupta. But their personalities were professionally and personally complementary. More importantly, they recognized that reality is undefeated and were ready to fix mistakes. Vinita’s responsibilities in the US had given her a global perspective and network in the pharma industry. She was a good listener, reacted thoughtfully to situations and sought harmony. Above all, she trusted her instincts.
Nilesh’s responsibilities aligned well with his data-driven focus, attention to detail and ability to build loyal teams, characterized by an amiable, self-deprecating sense of humour and clear delegation of responsibility. His success in running Lupin’s research and technical operations, as well as the India business, made him a strategic leader.
DBG’s values reinforced the ‘family first’ approach. And the siblings learned together from setbacks on their watch. They worked successfully together to make the US generics business the company’s largest contributor to topline and profit.
Vinita and Nilesh crafted a repair programme along five vectors: rationalization of portfolio, geography, costs and people; moving from generics to complex generics in the US and Europe; doubling down on India; fixing quality issues in manufacturing; and rebooting the leadership team for US generics, research, manufacturing, quality and HR.
Since the pandemic, respiratory has emerged as the company’s largest therapy area in the US and globally, accounting for a quarter of revenues and a significant portion of profits in 2025.
Increased efficiency and accelerated growth in India complemented the US restructuring. Building in-licensing agreements and acquiring brands helped Lupin expand its reach among doctors, hospitals and patients. The India sales force, which has always been a strength since DBG started Lupin, grew from 4,200 to over 10,000 in thirty-six divisions by 2024. The major chronic disease clusters of cardiology, diabetes and respiratory, with higher-value prescriptions, now account for 60% of the India region’s sales. Setting up new divisions, along with new product launches, ensured Lupin’s domestic business covered rapidly growing therapy areas, such as gastrointestinal and gynaecology, at scale.
Vinita and Nilesh rebuilt the team from the ground up, handpicking technically strong and hungry leaders, infusing fresh energy and world-class expertise into the organization. They also strengthened leadership across international markets and core technical functions.
Seven years after the crisis, Vinita and Nilesh succeeded in restoring Lupin’s standing and morale. Growth returned to double digits, and profitability rose back to peer levels.
